Ketamine hydrochloride intranasal - CCH Pharmaceuticals
Alternative Names: Ketamine hydrochloride intranasal spray - CCH PharmaceuticalsLatest Information Update: 12 Dec 2022
At a glance
- Originator CCH Pharmaceutical
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Neuroprotectants; Obesity therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cluster headache
Most Recent Events
- 12 Dec 2022 No development reported - Phase-II for Cluster headache in Denmark (Intranasal)
- 20 May 2020 CCH Pharmaceutical completes a phase II trial in Cluster headache in Denmark (Intranasal) (EudraCT2019-001260-29)
- 10 Sep 2019 Phase-II clinical trials in Cluster headache in Denmark (Intranasal) (EdudraCT2019-001260-29)